DrugChatter tracks how ChatGPT, Gemini, Perplexity, and others answer real questions about your molecules — flagging misinformation, off-label claims, and outdated safety language before they spread.
Starter
For a medical affairs or PV team tracking their first molecule's AI footprint.
20 tracked answers · billed monthly
Pro
For teams monitoring a small portfolio with daily misinformation scoring.
180 tracked answers · billed monthly
Advanced
For portfolios spanning multiple molecules, markets, and languages.
1,000 tracked answers · billed monthly
Enterprise
For global manufacturers needing custom model coverage and dedicated review.
Annual contracts only
Running a comms agency covering multiple manufacturers? Contact Us →
What's tracked, what's scored, and where DrugChatter connects to your other tools.
| Feature | Starter | Pro | Advanced | Enterprise |
|---|---|---|---|---|
| Coverage | ||||
| AI platforms monitored | ChatGPT | Choose 3 | All 6 | All 6 + custom |
| Molecules / brands tracked | 1 | 3 | 8 | Unlimited |
| Markets / languages | 1 | 1 | Multi-market | Unlimited |
| Tracking frequency | Weekly | Daily | Daily | Daily / real-time |
| Weekly Reports with recommended actions | ||||
| Executive Briefing | — | — | ✓ | ✓ |
| Business Development & Licensing | — | — | — | ✓ |
| Brand Marketing & Communications | — | — | — | ✓ |
| Clinical Development | — | — | — | ✓ |
| Competitive Intelligence | — | — | — | ✓ |
| Corporate Communications | — | — | — | ✓ |
| Digital Marketing | — | — | — | ✓ |
| Legal | — | — | — | ✓ |
| Market Access | — | — | — | ✓ |
| Medical Affairs | — | — | — | ✓ |
| Medical Information | — | — | — | ✓ |
| Patient Support Programs | — | — | — | ✓ |
| Pharmacovigilance | — | — | — | ✓ |
| Regulatory Affairs | — | — | — | ✓ |
| Sales Enablement | — | — | — | ✓ |
| Access | ||||
| Data export | — | — | ✓ | ✓ |
| IP-based sign-on | — | — | — | ✓ |
| Support | ||||
| Support channel | Email + chat | Priority email + chat | Dedicated support | |
Start a trial, or talk to us about which plan fits your portfolio.